Human RIG-I Antiviral Deficiency Caused by a Dominant-Negative Variant Locked in a Signaling-Inactive State
Solotchi, M.; Jing, H.; Gebauer, E.; Novick, S. J.; Pascal, B. D.; Tung, W.; Hanpude, P.; Zhang, Y.; Alba, C.; Saracino, A.; Laghetti, P.; Shaw, E. R.; Rosen, L. B.; Holland, S. M.; Lisco, A.; Dalgard, C. L.; Marcotrigiano, J.; Griffin, P. R.; Su, H. C.; Patel, S. S.
Show abstract
RIG-I is a cytosolic immune receptor that provides the first line of defense by detecting viral RNA and triggering antiviral responses. Its physiological role in humans remains unclear, as no patients with complete RIG-I deficiency have yet been reported. We identified a critically ill COVID-19 patient with severe RIG-I deficiency caused by heterozygous RIG-I G731R, a novel dominant loss-of-function variant. The G731R mutation in helicase motif VI disrupts the arginine finger, impairing the ATPase activity of RIG-I, but not its RNA-binding ability. However, viral RNA binding fails to expose the signaling domains, thereby impairing the IFN-{beta} response of G731R. Instead, G731R competes with wild-type RIG-I, exerting a dominant negative effect. The loss-of-function is caused by bulky-charged substitutions at G731, as alanine or leucine substitution results in an unexpected gain-of-function phenotype. These findings highlight the importance of uncompromised RIG-I function for human antiviral immunity and the pleiotropic effects of single mutations.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.